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The Editorial on the Research Topic
Focus on Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a serious systemic autoimmune disease. In the absence of 
specific targeted therapies, the majority of patients suffer inadequate disease control: a 20-year-
old diagnosed with SLE has up to a 10% chance of death before turning 40. SLE has long been 
considered the archetypical autoimmune disease, involving innate and adaptive mechanisms of 
inflammation and the generation of autoantibodies. A combination of genetic predisposition and 
environmental triggers leads to activation of the innate immune system. This results in the release 
of inflammatory mediators, including cytokines, which activate both innate and adaptive immune 
responses. Autoantibodies bind nucleic acids or cellular debris to form immune complexes, which 
further activate innate immune cells through Fc and toll-like receptors. This positive feedback loop 
eventually leads to systemic inflammation and tissue damage, which feeds back to further potentiate 
immune responses.
The apparent simplicity of this model belies the complexity seen by the physician. SLE presents 
with a broad range of symptoms and manifestations; some patients might develop renal disease, oth-
ers central nervous system complications and immune correlates with one “type” of SLE might not 
be same as for others. This makes diagnosis and treatment challenging. Current therapies are largely 
centered on non-specific immunosuppressants, including corticosteroids, which can have profound 
long-term side effects. The development of biological therapies for SLE has proven problematic, not 
least the fact that different cytokines and cells might play different roles at different stages, in the 
many different manifestations. Key to developing new treatments for SLE will be unraveling the 
complex interplay between the many arms of the immune system, from the underlying inflamma-
tion, to the specific roles of the many cell types involved. Moreover, the ability to stratify patients 
in a way that tells us what shape their disease will likely take would help us to embrace, rather than 
grapple with, the heterogeneous nature of SLE, perhaps allowing us to develop different drugs for 
different subsets of patients.
This Focus on Systemic Lupus Erythematosus brings together reviews from some of the world’s 
leading experts on SLE and the immunology that underlies SLE pathogenesis. Mahajan et al. present 
the arguments for cell death and deficiencies in dead cell clearance by phagocytes as a central 
pathway in the pathogenesis of SLE. This review highlights findings that suggest phagocytes from 
patients with SLE may have a defect in their ability to engulf and clear apoptotic cells, leading 
to the exposure of autoantigens and a break in B cell tolerance, resulting in the development of 
autoimmunity and SLE.
The role of T cell signaling and different T cell subsets is the focus of the review by Rother and 
van der Vlag. In particular, they focus on aberrant T cell receptor (TCR) signaling and roles of Th17 
and regulatory T cells (Tregs) in the development of SLE. Defects in the TCRζ chain, Syk kinase, 
and calcium signaling molecules, which have been associated with SLE, lead to the proliferation of 
autoreactive T cells, including Th17 cells. Concurrent with this is a reduction in numbers of Tregs 
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and impairment of their function, leading to inappropriate and 
poorly controlled inflammation.
Cytokines play a complex and critical role in the pathoetiology 
of SLE. Lang et al. focus specifically on macrophage migration 
inhibitory factor (MIF) and its roles in SLE pathogenesis. MIF 
was first identified in the 1960s, yet still remains surprisingly 
enigmatic. There are numerous ways in which MIF might be 
linked with SLE, and this is borne out both in mouse models and 
clinical studies. Moreover, polymorphisms that lead to increased 
MIF secretion have been linked with SLE in interesting ways, 
potentially conferring protection against development of SLE, 
but leading to more severe disease after onset. The potential of 
targeting MIF therapeutically is also discussed.
Plasmacytoid dendritic cells (pDCs) have recently been 
demonstrated to play an important role in the development of 
autoantibodies and SLE pathogenesis. These cells are potent 
producers of type I interferons (IFN-I), a family of cytokines that 
has been intricately linked with SLE. The role of pDCs in SLE and 
other diseases has been difficult to establish due to their rarity, 
difficulty to identify, and rapid but transient release of IFN-I. 
Huang et al. review the most recent developments in this exciting 
area of SLE research.
Germinal centers (GCs) are key sites of B cell clonal expan-
sion and affinity maturation. Also present in GC are follicular 
dendritic cells, which capture and retain antigen, T follicular 
helper cells, and T follicular regulatory cells. As Woods et  al. 
discuss, many mouse models of lupus are characterized by the 
spontaneous formation of GC, induced through a number of 
different mechanisms, both innate and adaptive. The review also 
highlights the role of B cell-activating factor (BAFF), defects in 
dead cell clearance in GC, and the potential for targeting GCs 
therapeutically in SLE.
Kidney injury in SLE (lupus nephritis) is a major cause of both 
morbidity and mortality, affecting over half of all SLE sufferers 
over the course of the disease. Yung and Chan focus on the 
contribution of anti-double stranded DNA (dsDNA) antibodies 
to the pathology of lupus nephritis. Deposition of anti-dsDNA 
antibody-containing immune complexes in the kidney is an 
initiating factor in lupus nephritis. However, as this review 
discusses, direct and indirect binding of anti-dsDNA antibodies 
to cross-reactive antigens in the kidney also plays a major role. 
The downstream effects of this, including proliferation, apoptosis, 
inflammation, and fibrogenesis, are highlighted. In addition, 
recent data are discussed suggesting that mycophenolic acid 
(MPA), the active ingredient of the drug mycophenolate mofetil, 
has specific inhibitory effects on anti-dsDNA-induced processes, 
independent of its known immunosuppressive actions.
Finally, Gottschalk et al. provide an important overview of the 
current state of play with regard to SLE therapies and where they 
may lead in the future. Individual biological targets, especially 
cytokines, are discussed. In particular, the potential of targeting 
IL-6, an important inflammatory mediator in SLE, is highlighted, 
as well as the idea of targeting multiple pathways with combina-
tion treatments.
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